Patents by Inventor Simon Richard Green
Simon Richard Green has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11186589Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: February 6, 2020Date of Patent: November 30, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
-
Patent number: 11180487Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: January 20, 2017Date of Patent: November 23, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
-
Patent number: 11136311Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: June 29, 2017Date of Patent: October 5, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
-
Patent number: 11001569Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as a cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: January 20, 2017Date of Patent: May 11, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
-
Publication number: 20210087182Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: January 20, 2017Publication date: March 25, 2021Inventors: Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET, Gerhard Max GROSS, Edgar JACOBY, Lieven MEERPOEL, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Simon Richard GREEN, George HYND
-
Publication number: 20210032267Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: February 6, 2020Publication date: February 4, 2021Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
-
Publication number: 20200109129Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or disorders.Type: ApplicationFiled: January 20, 2017Publication date: April 9, 2020Inventors: Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Gerhard Mx GROSS, Edgar JACOBY, Lieven MEERPOEL, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Simon Richard GREEN, George HYND
-
Publication number: 20190359598Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: June 29, 2017Publication date: November 28, 2019Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
-
Publication number: 20190119299Abstract: Fused aromatic bicyclic substituted 5-(2-amino-4-pyrimidinyl)-cyanoindoline derivatives (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: June 29, 2017Publication date: April 25, 2019Applicant: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
-
Patent number: 8975239Abstract: A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.Type: GrantFiled: August 6, 2013Date of Patent: March 10, 2015Assignee: Cyclacel LimitedInventors: Simon Richard Green, Ruth Mackay, Ian Neil Fleming
-
Publication number: 20140100187Abstract: A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.Type: ApplicationFiled: August 6, 2013Publication date: April 10, 2014Applicant: Cyclacel LimitedInventors: Simon Richard GREEN, Ruth MACKAY, Ian Neil FLEMING
-
Patent number: 8530445Abstract: A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.Type: GrantFiled: June 5, 2009Date of Patent: September 10, 2013Assignee: Cyclacel LimitedInventors: Simon Richard Green, Ruth Mackay, Ian Neil Fleming
-
Publication number: 20130005747Abstract: The present invention provides a method for determining whether or not a cancer subject is suitable for treatment with a purine-based roscovitine-like inhibitor, which method comprises the step of determining the ras status of the cancer, wherein a determination that the subject has mutant ras status is indicative that the subject is suitable for treatment with a purine-based roscovitine-like inhibitor.Type: ApplicationFiled: December 21, 2011Publication date: January 3, 2013Applicants: Cyclacel Limited, The General Hospital Corporation d/b/a Massachusetts General Hospital, The Trustees of Dartmouth CollegeInventors: Simon Richard GREEN, Judy H. CHIAO, Jeffery SETTLEMAN, Ethan DMITROVSKY, Fabrizio Vittorio GALIMBERTI
-
Publication number: 20110207692Abstract: A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.Type: ApplicationFiled: June 5, 2009Publication date: August 25, 2011Applicant: CYCLACEL LIMITEDInventors: Simon Richard Green, Ruth Mackay, Ian Neil Fleming
-
Patent number: 7772207Abstract: A first aspect of the invention relates to a combination comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a CDK inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.Type: GrantFiled: December 3, 2004Date of Patent: August 10, 2010Assignee: Cyclacel LimitedInventors: Simon Richard Green, Roger Neil Sleigh
-
Patent number: 7026278Abstract: A rinse-added fabric treatment composition having a rinse aid increases the rinse capacity of an aqueous rinse bath solution for removing laundry residue from laundered fabrics. When properly diluted in water, the rinse-added fabric treatment composition provides a rinse bath solution having a rinsing capacity of greater than 1. In addition, a rinse-added fabric treatment composition reduces the surfactant residue on a fabric, and includes from about 0.05% to about 10% of a residue reduction agent, a suds suppresser, and the balance adjunct ingredients. The residue reduction agent is selected from a cationic residue reduction agent, a zwitterionic residue reduction agent, and a combination thereof. Moreover, methods for reducing surfactant residue on fabric and a method for reducing the amount of water used in a rinsing step of a laundry process are included. A kit for improving the rinsing capacity of water includes a rinse-added fabric treatment composition and an instruction set.Type: GrantFiled: June 20, 2001Date of Patent: April 11, 2006Assignee: The Procter & Gamble CompanyInventors: Kenneth Nathan Price, Jean-Luc Philippe Bettiol, Nicola Kay Brown, Simon Richard Green, Li Li, Helen Frances O'Connor, Massimo Morini
-
Publication number: 20020111285Abstract: A rinse-added fabric treatment composition having a rinse aid increases the rinse capacity of an aqueous rinse bath solution for removing laundry residue from laundered fabrics. When properly diluted in water, the rinse-added fabric treatment composition provides a rinse bath solution having a rinsing capacity of greater than 1. In addition, a rinse-added fabric treatment composition reduces the surfactant residue on a fabric, and includes from about 0.05% to about 10% of a residue reduction agent, a suds suppresser, and the balance adjunct ingredients. The residue reduction agent is selected from a cationic residue reduction agent, a zwitterionic residue reduction agent, and a combination thereof. Moreover, methods for reducing surfactant residue on fabric and a method for reducing the amount of water used in a rinsing step of a laundry process are included. A kit for improving the rinsing capacity of water includes a rinse-added fabric treatment composition and an instruction set.Type: ApplicationFiled: June 20, 2001Publication date: August 15, 2002Inventors: Kenneth Nathan Price, Jean-Luc Philippe Bettiol, Nicola Kay Brown, Simon Richard Green, Li Li, Helen Frances O'Connor, Massimo Morini